» Home » CAD » Rheumatology » Autoimmune Disorder » Rheumatoid arthritis
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Rheumatology » Autoimmune Disorder » Rheumatoid arthritis
Background
Rheumatoid arthritis is a systemic autoimmune disease characterized by extra-articular involvement and inflammatory arthritis. It is a chronic inflammatory condition with no known cause that primarily affects synovial joints. Left untreated, it often extends in tiny peripheral joints, develops to encompass proximal joints, and is frequently symmetric.
Joint deterioration is caused by cartilage and bone loss over time due to joint inflammation. Early rheumatoid arthritis is characterized by symptoms that have been present for less than six months, while established rheumatoid arthritis is characterized by symptoms that have been present for more than six months.
Epidemiology
In the United States and other western countries of northern Europe, the yearly incidence of RA is around 40 per 100,000 people. Epidemiologic statistics indicate that women are more likely than males to acquire RA, with a lifetime risk of 3.6% for women and 1.7% for men. RA risk also increases with age, attaining its highest occurrence between the ages of 65 and 80.
First-degree relatives are three times more likely to have RA than second-degree relatives, with a two-fold increased risk. There are currently several possible genetic predispositions that may be used to explain this discovery. The HLA-DRB1 region has the highest genetic propensity for RA.
Anatomy
Pathophysiology
Patients with rheumatoid arthritis have antibodies against citrullinated proteins. Citrulline is an amino acid produced by peptidyl arginine deaminases when it modifies arginyl residues post-translationally. These antibodies are known as anti-citrullinated protein antibodies. IgA, IgG, or IgM isotypes of ACPA are possible. Fibronectin, vimentin, histones, fibrinogen, and type 2 collagen are examples of self-proteins with citrullinated residues that ACPA may bind.
Complement is activated when antibodies attach to proteins. Seropositive RA refers to the presence of antibodies in rheumatoid arthritis. The repetitive stimulation of innate immunity is believed to be the mechanism underlying environment-triggered RA. Smoking causes alveolar macrophages to produce peptidyl arginine deiminase, which causes arginine to be converted to citrulline in the airway.
This procedure produces a neoantigen that triggers an immune response and causes the development of antibodies against citrullinated proteins. Antibodies against post-translationally modified proteins, known as anti-carbamylated proteins, are linked to RA. Lysine is changed into homocitrulline by the chemical process of carbamylation, which is mediated by cyanide.
Homocitrulline shares a molecular structure with citrulline; however, anti-CarP antibodies, which are different, have been linked to RA in both ACPA-positive and ACPA-negative individuals. Antibodies against anti-acetylated proteins have recently been linked to RA in about 40% of patients, mainly in seropositive individuals. The relationship between RA and microbiome dysbiosis may be established via the enzymatic process of acetylation, which is assumed to be mediated by bacteria.
Etiology
The cause of RA is uncertain. It is believed to be the outcome of the interaction between a patient’s environment and genotype. For seropositive rheumatoid arthritis and seronegative rheumatoid arthritis, the heritability ranges from 40% to 65%, HLA-DRB1*01, HLA-DRB1*04, and HLA-DRB1*10 alleles have been linked to an increased risk of rheumatoid arthritis.
These HLA-DRB1 alleles have the shared epitope, which has been linked to an increased risk of developing RA, in the third hypervariable region of their DRB1 chain, as well as a length of conserved five amino acid sequences. It has been proposed that variation in the genes for IL-10 and signal transducers and activators of transcription (STAT)-4 also contributes to RA susceptibility.
Genes for PTPN2, MIR146A, and PSORS1C1 have single nucleotide polymorphisms that are linked to severe disease. Rheumatoid arthritis has also been linked to changes in the gut microbiome’s structure and operation. Rheumatoid arthritis patients experience dysbiosis, a change in the gut microbiome’s composition, wherein these patients have less diversity in their gut microbiota than healthy people.
Genetics
Prognostic Factors
Rheumatoid arthritis is a degenerative disease with no effective cure. All individuals will have multiple exacerbations, and treatment often ends with poor results, including higher disability and death rates. Early intervention within six months of the beginning of symptoms has increased functional capacity and reduced disease activity, as indicated by the number of swollen and sensitive joints.
However, the death rate in individuals getting early therapy and late treatment six months after the onset of symptoms is similar, and both are notably better than no treatment. Within 10 years of the diagnosis, 40% of RA patients will experience a functional impairment that limits their ability to work and perform everyday tasks.
The association between rheumatoid arthritis and atherosclerotic cardiovascular disease that accelerates coronary artery disease is the most notable aspect of this interaction. In these individuals, rheumatoid arthritis increases the risk of early mortality by increasing the risk of heart disease, lung conditions, and cancer.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
10
mg
Tablet
Oral
once a day
25 - 50
mg
Orally
once a day
90
mg
Tablet
Oral
once a day
400 mg immediate release 2 times daily
Or
300 mg immediate release 2 to 3 times a day
Or
500 mg immediate release 2 times a day
Or
400 mg to 1 g extended release once a day
≤10 mg/day orally Immediate release
5 mg/day orally Delayed release
Maintenance: low dose taken at bedtime to decrease morning stiffness with rheumatoid arthritis (RA)
≤10 mg/day orally Immediate release
5 mg/day orally Delayed release
Maintenance: low dose taken at bedtime to decrease morning stiffness with rheumatoid arthritis (RA)
3
g
oraly
in divided doses as needed
0.5-1 g/day delayed release orally divided 2x; increase weekly 2 g/day 2x; if response inadequate, may increase to 3 g/day
300 - 600
mg
Tablets
Orally
every 8 hrs
Immediate release:
25 - 50
mg
Tablet
Orally
every 12 hrs
Do not exceed 200mg/day
Extended release-75-150mg/day orally in single dose or divided every 12 hours
In case of renal impairment, 500 mg orally once daily:
1000
mg
Tablet
Orally
once a day
400
mg
Solution
Subcutaneous (SC)
every 2 weeks
400 - 600
mg
Tablet
Orally
once a day
Immediate release:
75
mg
Tablet
Orally
every 8 hrs
50mg orally every 6 hours
Extended release-200mg orally every day
50 mg subcutaneous (SC) every Month
Or
2 mg/kg IV at weeks 0 and week 4, then every 8Weeks
40
mg
Solution
Subcutaneous (SC)
every two weeks
5-7.5mg orally every day
Initial dose:125-250mg/day orally
Maintenance dose: If there is no improvement and the patient tolerates it, the dose may be increased by an additional 125–250 mg every 1-3 months, up to 500–750 mg daily
gold sodium thiomalate (Discontinued)
Indicated in patients with active rheumatoid arthritis who have failed trials of NSAIDs
1st week- 10 mg intramuscularly
2nd week- 25 mg intramuscularly
Later every week for 20 weeks, 25-50 mg intramuscularly, or until toxicity is achieved
Streamline the dose to 50 mg
intramuscularly every 2-4 weeks
The drug is not recommended when CrCl is less than 50 ml/min
Indicated in patients with active rheumatoid arthritis who have failed trials of NSAIDs
6 mg orally each day divided twice daily
Increase the dose to 9 mg/day divided thrice daily for 3 months
br>
After 3 months, if no response is seen, discontinue the drug
Take one tablet orally two times a day, ensuring that at least 30 minutes before the meal
choline magnesium trisalicylate
1000-3000 mg orally 2-3 times a day
Extract without tetracyclic oxindole alkaloids: take 60 mg orally three times daily
Tea
Infuse 2 to 2.5 grams of crushed rose hips in 150 ml boiling water for 10 to 15 minutes, then filter the liquid before consuming
Supplement
500 to 750 mg daily, preferably taken with food
Extract: take 3600 mg daily
diclofenac potassium- 50 mg orally 2-3 times daily
diclofenac sodium- 50 mg orally thrice daily or 75 mg orally every 12 hours
Extended-release- 100 mg orally once daily, may increase the dose to 100 mg every 12 hours
diclofenac potassium- 50 mg orally 2-3 times daily
diclofenac sodium- 50 mg orally thrice daily or 75 mg orally every 12 hours
Extended-release- 100 mg orally once daily, may increase the dose to 100 mg every 12 hours
50mg/200mcg as 1 tablet orally thrice daily
Do not increase the dose of misoprostol to more than 200 mcg/dose or 800 mcg each day
75mg/200mcg as 1 tablet orally thrice daily
Do not increase the dose of misoprostol to more than 200 mcg/dose or 800 mcg each day
If the dose is not tolerated, reduce the frequency to twice daily
Neoral or Gengraf: Administer 1.25 mg/kg orally twice a day
can increase the dose by 0.5 to 0.75 mg/kg/day after 8 weeks, and if needed again after 12 weeks, Do not exceed 4 mg/kg in a day
If no improvement is shown after 16 weeks, discontinue.
200 mg by subcutaneous every 2 weeks
Those with slightly to severely active rheumatoid arthritis (RA) who have not responded well or have become intolerable to at least one disease-modifying antirheumatic medication should take this medication (DMARDs)
MTX (methotrexate) or other traditional DMARDs may be combined with it or used as a monotherapy
Dosage Modifications
Hold off treatment until the infection is under control if it is severe or opportunistic
ANS
>1000 cells/mm3: Continue administering dose
500 to 1000 cells/mm3: Hold therapy off until ANC >1000; then, resume at 150 mg
Every two week, and then as clinically necessary, raise to 200 mg every 2 week
500 cells/mm3 or less: Stop
Low Platelets
50,000–100,000 cells/mm3 Continue treatment at 150 mg every two weeks and then raise it to 200 mg every two weeks as necessary until platelets reach more than100,000
<50,000 cells/mm3: Stop if verified by additional tests
PMR
Platelet count <100,000/mm3 for Thrombocytopenia
Neutropenia should be stopped
No research has been done on dosage adjustments for patients with these illnesses and PMR
Renal impairment
Mild-to-moderate: No dose adjustment is necessary
Severe: No study performed
Hepatic impairment
No study performed
Dosing Considerations
Before to starting therapy, check your platelet count. Then, check your platelets 4 to 8 weeks later and then every 3 months after that
Before beginning, check for latent tuberculosis (TB); if positive, discuss treating for TB first before using sarilumab
Because there is a higher risk of immunosuppression and infection when biological DMARDs are administered together, this should be avoided
Coadministration with biological DMARDs has not been thoroughly researched
Not more than 1800 mg each day
200 to 600 mg orally every eight hours
Administration
Take with 8-to-12-ounce water to ignore gastro-intestinal effects
1.2 gm orally each day in 2 to 4 divided doses
Dose Adjustments
In the case of renal impairment;
when CrCl is 50-75 ml/min, reduce the dose by 1/3rd to 1/2nd
when CrCl is less than 50 ml/min, reduce the dose by 1/2nd to 2/3rd
Take a dose of 250 mg orally three times a day
IV bolus
weight <60 kg: 500 mg
weight 60-100 kg: 750 mg
weight >100 kg: 1000 mg
Maintenance: Repeat the aforementioned dose every two weeks for two weeks, then every four weeks
Subcutaneous (SC)
You can start SC with or without an IV loading dose
Give the first SC injection if an IV loading dose is taken within a day following the infusion
125 mg SC every 7 days
Making the switch from IV to SC:
Instead of the planned IV dosage, administer the first SC dose
Administer 2g twice a day.
Do not exceed 6g in a day.
Analgesia
Administer 2g twice a day.
Osteoarthritis
Administer 2g twice a day.
Take a dose of 12 mg daily in 2 to 3 divided doses
Daily dose not more than 16 mg
Take a dose of 10 to 20 mg orally one time daily
<2 years: safety and efficacy not established
2-14 years:1-2mg/kg/day orally every 6-12hours.Do not exceed 4mg/kg/day
>14 years:25-50 mg orally/per rectum every 8-12 hours
Safety and efficacy are not seen in pediatrics:
choline magnesium trisalicylate
500-1500 mg orally 2-3 times a day
For more than 60 years, 300 mg twice daily
Dose Adjustments
In the case of renal impairment;
when CrCl is 50-75 ml/min, reduce the dose by 1/3rd to 1/2nd
when CrCl is less than 50 ml/min, reduce the dose by 1/2nd to 2/3rd
Future Trends
References
www.ncbi.nlm.nih.gov/books/NBK441999/
ADVERTISEMENT
» Home » CAD » Rheumatology » Autoimmune Disorder » Rheumatoid arthritis
Rheumatoid arthritis is a systemic autoimmune disease characterized by extra-articular involvement and inflammatory arthritis. It is a chronic inflammatory condition with no known cause that primarily affects synovial joints. Left untreated, it often extends in tiny peripheral joints, develops to encompass proximal joints, and is frequently symmetric.
Joint deterioration is caused by cartilage and bone loss over time due to joint inflammation. Early rheumatoid arthritis is characterized by symptoms that have been present for less than six months, while established rheumatoid arthritis is characterized by symptoms that have been present for more than six months.
In the United States and other western countries of northern Europe, the yearly incidence of RA is around 40 per 100,000 people. Epidemiologic statistics indicate that women are more likely than males to acquire RA, with a lifetime risk of 3.6% for women and 1.7% for men. RA risk also increases with age, attaining its highest occurrence between the ages of 65 and 80.
First-degree relatives are three times more likely to have RA than second-degree relatives, with a two-fold increased risk. There are currently several possible genetic predispositions that may be used to explain this discovery. The HLA-DRB1 region has the highest genetic propensity for RA.
Patients with rheumatoid arthritis have antibodies against citrullinated proteins. Citrulline is an amino acid produced by peptidyl arginine deaminases when it modifies arginyl residues post-translationally. These antibodies are known as anti-citrullinated protein antibodies. IgA, IgG, or IgM isotypes of ACPA are possible. Fibronectin, vimentin, histones, fibrinogen, and type 2 collagen are examples of self-proteins with citrullinated residues that ACPA may bind.
Complement is activated when antibodies attach to proteins. Seropositive RA refers to the presence of antibodies in rheumatoid arthritis. The repetitive stimulation of innate immunity is believed to be the mechanism underlying environment-triggered RA. Smoking causes alveolar macrophages to produce peptidyl arginine deiminase, which causes arginine to be converted to citrulline in the airway.
This procedure produces a neoantigen that triggers an immune response and causes the development of antibodies against citrullinated proteins. Antibodies against post-translationally modified proteins, known as anti-carbamylated proteins, are linked to RA. Lysine is changed into homocitrulline by the chemical process of carbamylation, which is mediated by cyanide.
Homocitrulline shares a molecular structure with citrulline; however, anti-CarP antibodies, which are different, have been linked to RA in both ACPA-positive and ACPA-negative individuals. Antibodies against anti-acetylated proteins have recently been linked to RA in about 40% of patients, mainly in seropositive individuals. The relationship between RA and microbiome dysbiosis may be established via the enzymatic process of acetylation, which is assumed to be mediated by bacteria.
The cause of RA is uncertain. It is believed to be the outcome of the interaction between a patient’s environment and genotype. For seropositive rheumatoid arthritis and seronegative rheumatoid arthritis, the heritability ranges from 40% to 65%, HLA-DRB1*01, HLA-DRB1*04, and HLA-DRB1*10 alleles have been linked to an increased risk of rheumatoid arthritis.
These HLA-DRB1 alleles have the shared epitope, which has been linked to an increased risk of developing RA, in the third hypervariable region of their DRB1 chain, as well as a length of conserved five amino acid sequences. It has been proposed that variation in the genes for IL-10 and signal transducers and activators of transcription (STAT)-4 also contributes to RA susceptibility.
Genes for PTPN2, MIR146A, and PSORS1C1 have single nucleotide polymorphisms that are linked to severe disease. Rheumatoid arthritis has also been linked to changes in the gut microbiome’s structure and operation. Rheumatoid arthritis patients experience dysbiosis, a change in the gut microbiome’s composition, wherein these patients have less diversity in their gut microbiota than healthy people.
Rheumatoid arthritis is a degenerative disease with no effective cure. All individuals will have multiple exacerbations, and treatment often ends with poor results, including higher disability and death rates. Early intervention within six months of the beginning of symptoms has increased functional capacity and reduced disease activity, as indicated by the number of swollen and sensitive joints.
However, the death rate in individuals getting early therapy and late treatment six months after the onset of symptoms is similar, and both are notably better than no treatment. Within 10 years of the diagnosis, 40% of RA patients will experience a functional impairment that limits their ability to work and perform everyday tasks.
The association between rheumatoid arthritis and atherosclerotic cardiovascular disease that accelerates coronary artery disease is the most notable aspect of this interaction. In these individuals, rheumatoid arthritis increases the risk of early mortality by increasing the risk of heart disease, lung conditions, and cancer.
10
mg
Tablet
Oral
once a day
25 - 50
mg
Orally
once a day
90
mg
Tablet
Oral
once a day
400 mg immediate release 2 times daily
Or
300 mg immediate release 2 to 3 times a day
Or
500 mg immediate release 2 times a day
Or
400 mg to 1 g extended release once a day
≤10 mg/day orally Immediate release
5 mg/day orally Delayed release
Maintenance: low dose taken at bedtime to decrease morning stiffness with rheumatoid arthritis (RA)
≤10 mg/day orally Immediate release
5 mg/day orally Delayed release
Maintenance: low dose taken at bedtime to decrease morning stiffness with rheumatoid arthritis (RA)
3
g
oraly
in divided doses as needed
0.5-1 g/day delayed release orally divided 2x; increase weekly 2 g/day 2x; if response inadequate, may increase to 3 g/day
300 - 600
mg
Tablets
Orally
every 8 hrs
Immediate release:
25 - 50
mg
Tablet
Orally
every 12 hrs
Do not exceed 200mg/day
Extended release-75-150mg/day orally in single dose or divided every 12 hours
In case of renal impairment, 500 mg orally once daily:
1000
mg
Tablet
Orally
once a day
400
mg
Solution
Subcutaneous (SC)
every 2 weeks
400 - 600
mg
Tablet
Orally
once a day
Immediate release:
75
mg
Tablet
Orally
every 8 hrs
50mg orally every 6 hours
Extended release-200mg orally every day
50 mg subcutaneous (SC) every Month
Or
2 mg/kg IV at weeks 0 and week 4, then every 8Weeks
40
mg
Solution
Subcutaneous (SC)
every two weeks
5-7.5mg orally every day
Initial dose:125-250mg/day orally
Maintenance dose: If there is no improvement and the patient tolerates it, the dose may be increased by an additional 125–250 mg every 1-3 months, up to 500–750 mg daily
gold sodium thiomalate (Discontinued)
Indicated in patients with active rheumatoid arthritis who have failed trials of NSAIDs
1st week- 10 mg intramuscularly
2nd week- 25 mg intramuscularly
Later every week for 20 weeks, 25-50 mg intramuscularly, or until toxicity is achieved
Streamline the dose to 50 mg
intramuscularly every 2-4 weeks
The drug is not recommended when CrCl is less than 50 ml/min
Indicated in patients with active rheumatoid arthritis who have failed trials of NSAIDs
6 mg orally each day divided twice daily
Increase the dose to 9 mg/day divided thrice daily for 3 months
br>
After 3 months, if no response is seen, discontinue the drug
Take one tablet orally two times a day, ensuring that at least 30 minutes before the meal
choline magnesium trisalicylate
1000-3000 mg orally 2-3 times a day
Extract without tetracyclic oxindole alkaloids: take 60 mg orally three times daily
Tea
Infuse 2 to 2.5 grams of crushed rose hips in 150 ml boiling water for 10 to 15 minutes, then filter the liquid before consuming
Supplement
500 to 750 mg daily, preferably taken with food
Extract: take 3600 mg daily
diclofenac potassium- 50 mg orally 2-3 times daily
diclofenac sodium- 50 mg orally thrice daily or 75 mg orally every 12 hours
Extended-release- 100 mg orally once daily, may increase the dose to 100 mg every 12 hours
diclofenac potassium- 50 mg orally 2-3 times daily
diclofenac sodium- 50 mg orally thrice daily or 75 mg orally every 12 hours
Extended-release- 100 mg orally once daily, may increase the dose to 100 mg every 12 hours
50mg/200mcg as 1 tablet orally thrice daily
Do not increase the dose of misoprostol to more than 200 mcg/dose or 800 mcg each day
75mg/200mcg as 1 tablet orally thrice daily
Do not increase the dose of misoprostol to more than 200 mcg/dose or 800 mcg each day
If the dose is not tolerated, reduce the frequency to twice daily
Neoral or Gengraf: Administer 1.25 mg/kg orally twice a day
can increase the dose by 0.5 to 0.75 mg/kg/day after 8 weeks, and if needed again after 12 weeks, Do not exceed 4 mg/kg in a day
If no improvement is shown after 16 weeks, discontinue.
200 mg by subcutaneous every 2 weeks
Those with slightly to severely active rheumatoid arthritis (RA) who have not responded well or have become intolerable to at least one disease-modifying antirheumatic medication should take this medication (DMARDs)
MTX (methotrexate) or other traditional DMARDs may be combined with it or used as a monotherapy
Dosage Modifications
Hold off treatment until the infection is under control if it is severe or opportunistic
ANS
>1000 cells/mm3: Continue administering dose
500 to 1000 cells/mm3: Hold therapy off until ANC >1000; then, resume at 150 mg
Every two week, and then as clinically necessary, raise to 200 mg every 2 week
500 cells/mm3 or less: Stop
Low Platelets
50,000–100,000 cells/mm3 Continue treatment at 150 mg every two weeks and then raise it to 200 mg every two weeks as necessary until platelets reach more than100,000
<50,000 cells/mm3: Stop if verified by additional tests
PMR
Platelet count <100,000/mm3 for Thrombocytopenia
Neutropenia should be stopped
No research has been done on dosage adjustments for patients with these illnesses and PMR
Renal impairment
Mild-to-moderate: No dose adjustment is necessary
Severe: No study performed
Hepatic impairment
No study performed
Dosing Considerations
Before to starting therapy, check your platelet count. Then, check your platelets 4 to 8 weeks later and then every 3 months after that
Before beginning, check for latent tuberculosis (TB); if positive, discuss treating for TB first before using sarilumab
Because there is a higher risk of immunosuppression and infection when biological DMARDs are administered together, this should be avoided
Coadministration with biological DMARDs has not been thoroughly researched
Not more than 1800 mg each day
200 to 600 mg orally every eight hours
Administration
Take with 8-to-12-ounce water to ignore gastro-intestinal effects
1.2 gm orally each day in 2 to 4 divided doses
Dose Adjustments
In the case of renal impairment;
when CrCl is 50-75 ml/min, reduce the dose by 1/3rd to 1/2nd
when CrCl is less than 50 ml/min, reduce the dose by 1/2nd to 2/3rd
Take a dose of 250 mg orally three times a day
IV bolus
weight <60 kg: 500 mg
weight 60-100 kg: 750 mg
weight >100 kg: 1000 mg
Maintenance: Repeat the aforementioned dose every two weeks for two weeks, then every four weeks
Subcutaneous (SC)
You can start SC with or without an IV loading dose
Give the first SC injection if an IV loading dose is taken within a day following the infusion
125 mg SC every 7 days
Making the switch from IV to SC:
Instead of the planned IV dosage, administer the first SC dose
Administer 2g twice a day.
Do not exceed 6g in a day.
Analgesia
Administer 2g twice a day.
Osteoarthritis
Administer 2g twice a day.
Take a dose of 12 mg daily in 2 to 3 divided doses
Daily dose not more than 16 mg
Take a dose of 10 to 20 mg orally one time daily
<2 years: safety and efficacy not established
2-14 years:1-2mg/kg/day orally every 6-12hours.Do not exceed 4mg/kg/day
>14 years:25-50 mg orally/per rectum every 8-12 hours
Safety and efficacy are not seen in pediatrics:
choline magnesium trisalicylate
500-1500 mg orally 2-3 times a day
For more than 60 years, 300 mg twice daily
Dose Adjustments
In the case of renal impairment;
when CrCl is 50-75 ml/min, reduce the dose by 1/3rd to 1/2nd
when CrCl is less than 50 ml/min, reduce the dose by 1/2nd to 2/3rd
www.ncbi.nlm.nih.gov/books/NBK441999/
Rheumatoid arthritis is a systemic autoimmune disease characterized by extra-articular involvement and inflammatory arthritis. It is a chronic inflammatory condition with no known cause that primarily affects synovial joints. Left untreated, it often extends in tiny peripheral joints, develops to encompass proximal joints, and is frequently symmetric.
Joint deterioration is caused by cartilage and bone loss over time due to joint inflammation. Early rheumatoid arthritis is characterized by symptoms that have been present for less than six months, while established rheumatoid arthritis is characterized by symptoms that have been present for more than six months.
In the United States and other western countries of northern Europe, the yearly incidence of RA is around 40 per 100,000 people. Epidemiologic statistics indicate that women are more likely than males to acquire RA, with a lifetime risk of 3.6% for women and 1.7% for men. RA risk also increases with age, attaining its highest occurrence between the ages of 65 and 80.
First-degree relatives are three times more likely to have RA than second-degree relatives, with a two-fold increased risk. There are currently several possible genetic predispositions that may be used to explain this discovery. The HLA-DRB1 region has the highest genetic propensity for RA.
Patients with rheumatoid arthritis have antibodies against citrullinated proteins. Citrulline is an amino acid produced by peptidyl arginine deaminases when it modifies arginyl residues post-translationally. These antibodies are known as anti-citrullinated protein antibodies. IgA, IgG, or IgM isotypes of ACPA are possible. Fibronectin, vimentin, histones, fibrinogen, and type 2 collagen are examples of self-proteins with citrullinated residues that ACPA may bind.
Complement is activated when antibodies attach to proteins. Seropositive RA refers to the presence of antibodies in rheumatoid arthritis. The repetitive stimulation of innate immunity is believed to be the mechanism underlying environment-triggered RA. Smoking causes alveolar macrophages to produce peptidyl arginine deiminase, which causes arginine to be converted to citrulline in the airway.
This procedure produces a neoantigen that triggers an immune response and causes the development of antibodies against citrullinated proteins. Antibodies against post-translationally modified proteins, known as anti-carbamylated proteins, are linked to RA. Lysine is changed into homocitrulline by the chemical process of carbamylation, which is mediated by cyanide.
Homocitrulline shares a molecular structure with citrulline; however, anti-CarP antibodies, which are different, have been linked to RA in both ACPA-positive and ACPA-negative individuals. Antibodies against anti-acetylated proteins have recently been linked to RA in about 40% of patients, mainly in seropositive individuals. The relationship between RA and microbiome dysbiosis may be established via the enzymatic process of acetylation, which is assumed to be mediated by bacteria.
The cause of RA is uncertain. It is believed to be the outcome of the interaction between a patient’s environment and genotype. For seropositive rheumatoid arthritis and seronegative rheumatoid arthritis, the heritability ranges from 40% to 65%, HLA-DRB1*01, HLA-DRB1*04, and HLA-DRB1*10 alleles have been linked to an increased risk of rheumatoid arthritis.
These HLA-DRB1 alleles have the shared epitope, which has been linked to an increased risk of developing RA, in the third hypervariable region of their DRB1 chain, as well as a length of conserved five amino acid sequences. It has been proposed that variation in the genes for IL-10 and signal transducers and activators of transcription (STAT)-4 also contributes to RA susceptibility.
Genes for PTPN2, MIR146A, and PSORS1C1 have single nucleotide polymorphisms that are linked to severe disease. Rheumatoid arthritis has also been linked to changes in the gut microbiome’s structure and operation. Rheumatoid arthritis patients experience dysbiosis, a change in the gut microbiome’s composition, wherein these patients have less diversity in their gut microbiota than healthy people.
Rheumatoid arthritis is a degenerative disease with no effective cure. All individuals will have multiple exacerbations, and treatment often ends with poor results, including higher disability and death rates. Early intervention within six months of the beginning of symptoms has increased functional capacity and reduced disease activity, as indicated by the number of swollen and sensitive joints.
However, the death rate in individuals getting early therapy and late treatment six months after the onset of symptoms is similar, and both are notably better than no treatment. Within 10 years of the diagnosis, 40% of RA patients will experience a functional impairment that limits their ability to work and perform everyday tasks.
The association between rheumatoid arthritis and atherosclerotic cardiovascular disease that accelerates coronary artery disease is the most notable aspect of this interaction. In these individuals, rheumatoid arthritis increases the risk of early mortality by increasing the risk of heart disease, lung conditions, and cancer.
www.ncbi.nlm.nih.gov/books/NBK441999/
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
